Annovis Bio Files 8-K on Financials
Ticker: ANVS · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
Annovis Bio dropped an 8-K detailing its financials - check it for the latest numbers.
AI Summary
Annovis Bio, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company incorporated in Delaware and headquartered in Malvern, PA.
Why It Matters
This filing provides investors with an update on Annovis Bio's financial health and operational performance, which is crucial for evaluating the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not contain new material events or significant risk disclosures.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- August 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Malvern, PA (location) — Principal Executive Offices
- QR Pharma, Inc. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for Annovis Bio, Inc.?
The primary purpose of this 8-K filing is to report on Annovis Bio, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 15, 2024.
In which U.S. state is Annovis Bio, Inc. incorporated?
Annovis Bio, Inc. is incorporated in Delaware.
What is the principal executive office address for Annovis Bio, Inc.?
The principal executive office address for Annovis Bio, Inc. is 101 Lindenwood Drive, Suite 225, Malvern, PA 19355.
What was the former name of Annovis Bio, Inc.?
The former name of Annovis Bio, Inc. was QR Pharma, Inc.
Filing Stats: 441 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-08-15 07:15:54
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2421776d1_8k.htm (8-K) — 26KB
- tm2421776d1_ex99-1.htm (EX-99.1) — 20KB
- 0001104659-24-089913.txt ( ) — 223KB
- anvs-20240815.xsd (EX-101.SCH) — 3KB
- anvs-20240815_lab.xml (EX-101.LAB) — 33KB
- anvs-20240815_pre.xml (EX-101.PRE) — 22KB
- tm2421776d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On August 15, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits Exhibit No. Description 99.1 Press Release Dated August 15, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: August 15, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer